Clene (CLNN) Interest Expense : $-4.56 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Clene Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Clene's interest expense for the three months ended in Dec. 2023 was $ -1.20 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.56 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Clene's Operating Income for the three months ended in Dec. 2023 was $ -9.76 Mil. Clene's Interest Expense for the three months ended in Dec. 2023 was $ -1.20 Mil. Clene did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Clene Interest Expense Historical Data

The historical data trend for Clene's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Interest Expense Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.09

-0.95

-0.87

-3.30

-4.56

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial												-0.91	-1.07	-1.10	-1.19	-1.20

Clene Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.56 Mil.

Clene (NAS:CLNN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Clene's Interest Expense for the three months ended in Dec. 2023 was $-1.20 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-9.76 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $12.06 Mil.

Clene's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Clene did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Clene (CLNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

84C:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Executives

David J Matlin	director
Matthew Kiernan	director	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington	director, officer: Chief Executive Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Alison Mosca	director	26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay	director	177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc	10 percent owner	6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman	officer: Chief Medical Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown	officer: Chief Financial Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson	officer: Chief Science Officer	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121